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Seventy patients with 90 venous ulcers were randomly assigned to hydrocolloid or conven- 
tional dressing and compression therapy at four study centers. The ulcers had been present 
for a mean of 47.8 in the control and 46.2 weeks in the treatment group and 42% of all patients 
had recurrent ulcers. Ulcers treated with hydrocolloid dressings reduced 71% and control 
treated wounds reduced 43% in area after 7.2 weeks of treatment. Thirty-four percent of all 
ulcers healed. Mean time to healing was 7 weeks for the hydrocolloid dressing group and 8 
weeks for the control group. Most ulcers were less painful at final evaluation, but reduction in 
pain was more pronounced in hydrocolloid-dressed ulcers (p = 0.03). At baseline as well as 
during follow-up, significant differences between study centers were observed. Ulcers in 
patients in the United Kingdom were larger and less likely to heal (p = 0.001). Size of the ulcer 
at baseline was associated with treatment response and time to healing (p = 0.002). Percent 
reduction in ulcer area after 2 weeks was also correlated with treatment outcome (p = 0.004) 
and time to healing (p = 0.002). When all treatment outcome predictors were analyzed 
together, only percent reduction in area after 2 weeks remained statistically significant 
(p = 0.002), with percent reduction during the first 2 weeks of treatment >30% predicting 
healing. (Ann Vasc Surg 1994;8:356-362.) 
Ulceration of the lower extremities is estimated 
to affect 0.2% to 0.5% of the population, with 
ulceration secondary to venous insufficiency be- 
ing encountered most frequently. 13 Venous ul- 
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ceration is a major health problem, and unfor- 
tunately, fewer than 5% of patients with these 
ulcers are appropriate candidates for operative 
therapy. 4,s Successful nonoperative treatment re- 
quires accurate diagnosis, specific management  of 
predisposing conditions, and effective local care 
of the wound. 6 Basically there are two different 
types of wound dressings available to manage 
these wounds: conventional (nonocclusive) and 
occlusive dressings. Previous studies have shown 
that acute as well as chronic wounds dressed with 
occlusive dressings heal faster and are less pain- 
ful than wounds covered with conventional 
dressings. 711 However, results of chronic wound 
studies, including leg ulcers, are complicated by 
variables that are difficult to control, such as 
underlying pathology and patient compliance. 
We therefore conducted a study to evaluate the 
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effect of two different topical wound care regi- 
mens on venous ulcers; four different study sites 
were included so as to enroll a relatively large 
number of patients with the same primary di- 
agnosis. 
M A T E R I A L  A N D  M E T H O D S  
After Institutional Review Board or Ethics Com- 
mittee Approval was obtained, four study centers 
(Royal Liverpool Hospital, Liverpool, U.K., Queens 
Medical Center, Nottingham, U.K., University of 
Michigan Hospital, Ann Arbor, Mich., and Tulane 
University School of Medicine, New Orleans, La. ), 
started screening all patients eligible to partici- 
pate in the study. Patients with lower leg ulcer- 
ation secondary to venous stasis were eligible for 
study enrollment providing their ulcers were not 
infected (i.e., there was no evidence of periwound 
erythema, cellulitis, or edema). Patients with ul- 
cers resulting from arterial insufficiency, vasculi- 
tis, rheumatoid arthritis, sickle cell anemia, tu- 
mors, or other dermatologic conditions were ex- 
cluded from the study. Patients with deep dermal 
involvement and exposure of muscle, tendon, or 
bone were not enrolled in the study. After the 
patient history was obtained, the ulcer was irri- 
gated with normal saline solution and measured. 
Photographs with a centimeter label next to the 
wound were taken at baseline, at the follow-up 
dressing changes, and at the final evaluation. 
Ulcers were to be studied for a maximum of 10 
weeks, until healed, or until noncompliance or 
adverse experience required discontinuation of 
the treatment. Following the initial assessment, 
patients were randomly assigned to the study or 
control treatment. Study treatment consisted of 
application of a hydrocolloid dressing (HCD, Duo- 
DERM CGF dressing, ConvaTec, Skillman, N.J.) 
covered with a zinc oxide paste bandage (Unna's 
boot) and a gradient compression bandage. Pa- 
tients were told to wear the compression bandage 
during their working hours and received instruc- 
tion on the proper method of application. The 
study dressings were sized to extend at least 3 cm 
beyond the wound margin onto intact skin. The 
control treatment consisted of a paraffin-impreg- 
nated gauze dressing (Telfa, Kendall Healthcare 
Products, Inc., Mansfield, Mass.) in the United 
States or saline solution/Betadine-impregnated 
gauze dressings in the U.K. study centers. Appli- 
cation of the control dressings was followed by 
use of zinc oxide paste and compression bandage 
as described for the study treatment. Dressings 
were left in place for 7 days, at which time 
patients were asked to return to the clinic. No 
hydrotherapy or topical medications were used 
during the study, and patients were instructed to 
return earlier than the scheduled weekly visit if 
the wound became very uncomfortable and/or 
significant leakage of wound exudate occurred. 
Pain ratings (a verbal pain rating scale with 
0 = no pain and 10 = intolerable pain) were ob- 
tained at baseline and every subsequent clinic 
visit. If the ulcer had not healed at the final 
evaluation, the investigator completed a 3-point 
(improved, no change, or deteriorated) response 
to the treatment rating scale. In addition, patients 
were asked to rate the comfort, convenience, ease 
of use, and aesthetic appearance of their treat- 
ment  modality using a 10-point rating scale rang- 
ing from 0 (very comfortable and easy to use) to 
10 (very uncomfortable, difficult to use, or un- 
sightly). 
Data Analysis 
Reduction in ulcer area was quantified by tracing 
the photographs. The tracing was subsequently 
corrected for photographic magnification based 
on the centimeter label included in the picture. To 
compensate for initial differences in wound size 
the following formula was used to calculate per- 
cent reduction from baseline: 
%Reduction = 100 x (baseline - current size)/baseline 
The t test for independent samples was used to 
compare baseline patient and wound characteris- 
tics and analysis of variance was used to deter- 
mine the independent effects of dressing type and 
prognostic factors on pain and ulcer area at last 
follow-up. To compare proportions the chi-square 
test was used. To analyze trends in proportions 
the Mantel-Haensel test for trends was used. The 
Mantel-Haensel test for pooling over tables was 
used to control for differences among centers. 
Healing times for the groups were compared by 
means of the Kaplan-Meier product hmit curves 
and the log-rank test. All tests were performed at 
the 0.05 level of significance using the Statistical 
Analysis System (SAS Institute, Cary, N.C.). 
RESULTS 
Baseline Ulcer and Patient  Variables 
A total of 70 patients with 90 venous ulcers were 
enrolled in the study. Thirty-five were assigned to 
the control group and 35 were assigned to the 
study treatment. A little more than half (52%) of 
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all patients were men, and patients were equally 
distributed among treatment groups with respect 
to sex (p >0.05). Thirty of the 70 patients had 
recurrent ulcers. Of these, 13 were randomized to 
the treatment and 17 to the control group 
(p > 0.05). The mean age of patients in the treat- 
ment group was 65 (SE 3.3) compared with 60 
years old (SE 2.9) for the control group 
(p > 0.05). Ulcers had been present for a mean of 
47.8 weeks in the control and 46.2 weeks in the 
treatment group prior to study enrollment. How- 
ever, a significant difference in ulcer duration was 
found between study centers. At the U.K. centers 
only five patients had had their ulcer for < 14 
weeks, whereas at the U.S. centers 22 patients 
had had their current ulcer for <14 weeks 
(p = 0.003). No difference in baseline areas for 
the two groups was observed; the mean ulcer area 
for ulcers randomized to treatment was 2100 mm 2 
(SE 685) compared with 1983 m m  2 (SE 659) for 
the control group (p > 0.05). Mean baseline areas 
at the centers ranged from 883 m m  2 (SD 890) to 
3129 m m  2 (SD 3503), with mean ulcer areas 
being larger at the two U.K. study centers 
(p > 0.05). Pain at baseline also did not differ for 
treatment groups (mean 1.84, SD 1.83 for treat- 
ment and mean 2.11, SD 1.81 for control) (Fig. 1). 
However, pain at baseline did differ significantly 
at the study centers (p = 0.003) (Fig. 2). Al- 
though ulcers of shorter duration tended to be 
more painful at baseline, the differences failed to 
reach statistical significance (p = 0.07). 
F o l l o w - U p  a n d  R e s p o n s e  t o  T r e a t m e n t  
Seven patients in the control and nine in the 
treatment group withdrew from the study. In the 
control group three patients withdrew because of 
pain or discomfort, one patient developed celluli- 
tis requiring treatment with an antibiotic, one 
patient developed an infection, and two patients 
discontinued for reasons unrelated to the treat- 
ment. In the treatment group two patients devel- 
oped an infection, one patient withdrew for rea- 
sons of discomfort, and six withdrew for non- 
study related reasons. Patients were treated a 
mean of 7.2 weeks (range 1 to 10 weeks, SD 
3.04). During this time 25 ulcers healed, 11 in the 
treatment and 14 in the control group (p > 0.05). 
For ulcers that did not heal, wounds were rated as 
clinically improved in 31 (41%) of the HCD- 
treated and 28 (36%) of the control wounds. Four 
wounds in the treatment group and five in the 
control group deteriorated (p > 0.05). Response to 
treatment (healed vs. not healed) differed among 
treatment centers. In the U.S. study centers 22 
wounds (52%) healed compared with 9% of ulcers 
studied in the United Kingdom (p = 0.001). Of 
the 18 ulcers that were very painful at baseline 
(score >6), 11 (61%) healed. Conversely, of the 
23 ulcers that were not painful at all (score 0), 
only six (26%) healed. This difference was statis- 
tically significant (p = 0.03). However, when con- 
trolled for by study center, the relationship be- 
tween pain and treatment outcome was no longer 
apparent (p = 0.3). None of the other patient 
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Fig. 1. Baseline and final pain scores by treatment modality. 
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and  w o u n d  variables evaluated was found  to 
inf luence response to t r ea tmen t  (healed vs. not  
healed).  
T i m e  t o  H e a l i n g  a n d  F i n a l  U l c e r  A r e a  
The m e a n  t ime to heal ing for HCD wounds  was 
7.09 weeks ( SE 0.2) compared  wi th  8.2 weeks ( SE 
0.4) for controls (p >0.05) .  Analysis of the area 
data  showed that  the m e a n  percent  reduct ion  at 
the final evaluat ion was 71% (SD 4.3) for the 
HCD and 43% (SD 7.1) for the control  group 
(p > 0.05). Time unt i l  heal ing was related to base- 
line area, w i th  smaller ulcers (_< 185 m m  2) reach- 
ing 100% heal ing after  a m e a n  of 5.5 weeks  (SE 
0.7) compared  wi th  7 weeks (SE 0.2) for ulcers 
tha t  were  185 to 2150 m m  2 at baseline. The 
med ian  t ime to heal ing of wounds  that  were  
>2 1 5 0  m m  2 could not  be calculated since fewer 
t h an  50% of these ulcers healed (p = 0.002) (Fig. 
3 ). W h e n  control led for t r ea tmen t  modality, m e a n  
area at basel ine remained  a significant predictor  
of  t ime unt i l  heal ing (p -- 0.005). 
Time unt i l  heal ing by s tudy center  also differed 
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Fig. 2. Baseline and final pain scores by study center. 
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Fig. 3. Time until healing (Kaplan-Meier) curves by baseline area. 
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Fig. 4. Time until healing (Kaplan-Meier) curves by percent change in ulcer area after 2 weeks 
of treatment. 
significantly, with means ranging from 6 weeks 
(SE 0.3 for the Tulane and 0.5 for the Ann Arbor 
study center) to 7.9 and 10 weeks, respectively, for 
the United Kingdom study centers (p = 0.0001). 
When the effect of study center was controlled for 
by baseline area, the time to healing differences 
remained statistically significant (p -- 0.004). 
Percent reduction in ulcer area after 2 weeks of 
treatment was also predictive of time until heal- 
ing (Fig. 4). Also, final area (treatment outcome) 
was related to percent reduction in ulcer area 
after 2 weeks (p -- 0.004) and baseline area. The 
smallest ulcers had decreased a mean of 85% in 
size at the final evaluation, whereas the largest 
ulcers had decreased a mean of 7% in size 
(p = 0.005). However, when all variables that 
were found to correlate to treatment outcome 
(pain at baseline, study center, baseline area, and 
percent reduction in area after 2 weeks) were 
analyzed together for their relationship to reduc- 
tion in ulcer size at the final assessment, only 
percent reduction after 2 weeks remained statis- 
tically significant (p = 0.002). 
Pain and Pat ient  Sat isfact ion 
The mean pain scores at the final assessment 
were lower than the pain scores at baseline for 
both treatment groups; however, patients in the 
HCD treatment group reported significantly less 
pain at follow-up as compared to patients in the 
control group (see Fig. 1). Baseline pain was 
related to final pain, with 77% of patients who 
reported no pain at baseline reporting no pain at 
the final evaluation and with 41% of patients who 
reported a very painful ulcer (score > 6) at base- 
line indicating a very painful ulcer at the final 
evaluation (p = 0.0001). Pain at the final evalu- 
ation was also related to treatment center (see 
Fig. 2). However, after adjustment for differences 
among centers, little relationship between base- 
line and final pain was found (p -- 0.20). Patient 
satisfaction with treatment, recorded at the final 
evaluation, was related to baseline pain but not to 
center or ulcer duration. Patients with consider- 
able pain ( > 6) at baseline were more likely to be 
dissatisfied at the end of the study, regardless of 
treatment modality (p = 0.03). Patients at differ- 
ent study centers did not differ in their satisfac- 
tion with the treatment. Fourteen control patients 
(37%) and nine patients (25%) in the treatment 
group were not very satisfied (score >4) with 
their treatment modality. Conversely, 60% of the 
HCD and 50% of the control group rated their 
treatment as very comfortable, easy to use, and 
aesthetically pleasing (score _<2) (p = 0.3). 
D I S C U S S I O N  
The results of our study confirm the inherent 
difficulties of discerning a treatment effect in the 
management  of chronic wounds such as venous 
ulcers. Even though our population was restricted 
to patients diagnosed with venous ulcers only, 
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significant differences, unrelated to the treatment 
modalities studied, were found. First, the effect of 
the study center on treatment outcome, healing 
rates, and pain was significant. In one other 
international multicenter study of full-thickness 
leg ulcers these differences were not observed. ~2 
We found that ulcers in the U.K. study centers 
were usually larger and had existed for a longer 
period of time. This may have been caused by a 
more severe underlying pathology since time until 
healing still differed significantly among study 
centers even after controlling for the variables of 
baseline area and ulcer duration. Of course, pa- 
tient comphance may also have been different. In 
addition, with respect to the subjective variable 
pain, significant differences between centers were 
found; however, no trend was observed between 
continents. Given the sparsity of data comparing 
treatment results at different centers, it appears 
that care should be taken when interpreting 
treatment results of one study center and apply- 
ing it to another. 
None of the patient variables recorded affected 
treatment outcome. Increased patient age has 
previously been found to delay leg ulcer heal- 
ing. x2'~3 However, our patient population may have 
been too homogeneous in age to detect any dif- 
ferences. In our study, as well as reports from 
other investigators, baseline area was a signifi- 
cant predictor of time to healing. ~3"~4 Others have 
found none or only a marginal effect of baseline 
area on time to healing) 2"~'~ Whether or not 
these discrepancies are related to initial ulcer 
depth or other patient/ulcer variables remains to 
be investigated. Overall response to treatment 
was encouraging. Patients in the HCD group 
exhibited a decrease in area of 71%, and ulcers in 
the control group reduced a mean of 43% in size. 
Also, time to healing for HCD wounds was 7 
weeks compared with 8 weeks for controls. How- 
ever, the effect of the treatment center and the 
variability/effect of baseline area on percent re- 
duction on healing was so great that no statisti- 
cally significant differences between treatment 
groups could be found. 
Fear of infection has prevented some physi- 
cians from using Occlusive dressings. In our study 
the incidence of infection or cellulitis did not 
differ between treatment groups. Only one ulcer 
in the HCD and two ulcers in the control group 
became infected. These results confirm earlier 
published findings that clinical infections are rare 
in wounds covered with occlusive dressings. 17"~8 
Patients with the treatment dressing experi- 
enced significantly less pain as compared with 
controls. This effect of HCD treatment has also 
been reported by others. 6'7"1~ Pain was also cor- 
related with patient satisfaction. Even though the 
overall pain scores decreased in both treatment 
groups, patients who reported a lot of pain at 
baseline remained more likely to be dissatisfied 
with treatment. Satisfaction was not related to 
filial pain and only marginally related to treat- 
ment  modality, suggesting that patients who ex- 
perience a lot of ulcer pain when first seen are less 
likely to report being happy with their treatment. 
Caring for patients with chronic wounds and 
prescribing a treatment modality that encourages 
patient compliance remain a challenge. A treat- 
ment modality that reduces pain and a well- 
defined treatment plan may help. Traditionally, 
practitioners have prescribed treatments for at 
least 6 to 8 weeks before reevaluating the patients 
and/or the treatment modality prescribed. Our 
study results corroborate recently published re- 
search indicating that this reassessment should 
take place after 2 to 4 weeks. Cordts et al. 1~ found 
that the effect of treatment on chronic leg ulcers 
was most pronounced during the first 4 weeks of 
their study. Subsequently, Margolis et al. 19 found 
that ulcers with a positive initial healing rate 
during the first 4 weeks of treatment were more 
likely to heal, and van Rijswijk et al. 12 reported 
that percent reduction in ulcer area after 2 weeks 
was a predictor of both treatment outcome and 
time to healing. In our study population percent 
reduction after 2 weeks of treatment was also 
significantly related to treatment outcome (final 
area) and time to healing. The variable of percent 
reduction after 2 weeks of treatment was found 
to remain indicative of treatment outcome, even 
after adjustment of all other differences. Frequent 
ulcer measurements will help the clinician evalu- 
ate the efficacy of the treatment modafity pre- 
scribed and/or the level of patient comphance 
after as little as 2 to 4 weeks, possibly saving the 
patient weeks of ineffective treatment and dis- 
comfort. 
C O N C L U S I O N  
Patient characteristics, including compliance, as 
well as ulcer characteristics are important vari- 
ables in the management  of venous ulcers. Pa- 
tient compliance may be facilitated if the treat- 
ment modafity prescribed reduces pain and if the 
treatment plan is effective. Even though addi- 
tional controlled clinical studies are necessary, 
available data indicate that HCD treatment is 
safe, effective, and more likely to reduce pain 
362 Arnold et al. 
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than conventional dressings. Finally, frequent ul- 
cer measurements will help the clinician decide 
when to reevaluate patient compliance, underly- 
ing pathology, or the treatment modality pre- 
scribed. 
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